Literature DB >> 29629490

Long-Term Follow-Up Study of Liver-Related Outcome After Bilio-Pancreatic Diversion in Patients with Initial, Significant Liver Damage.

Edoardo G Giannini1, Claudia Coppo2, Chiara Romana2, Giovanni B Camerini3, Franco De Cian3, Nicola Scopinaro3, Francesco S Papadia3.   

Abstract

BACKGROUND: Obesity is associated with NAFLD, and bariatric surgery has significant impact on this liver disease, with reported improvement in hepatic fibrosis. AIMS: To investigate the effects of bariatric surgery on long-term liver disease-related outcome in obese patients with nonalcoholic fatty liver disease (NAFLD) and significant liver damage.
METHODS: This study included 56 NAFLD patients who underwent bilio-pancreatic diversion for morbid obesity and who had significant fibrosis at intraoperative liver biopsy. Data were analyzed at 1, 3, and 5 years of follow-up, and at the latest available visit in patients who had longer follow-up. We assessed the incidence of clinically relevant liver events (ascites, hepatic encephalopathy, portal hypertension-related bleeding, and jaundice) as well as modifications of a validated biochemical index such as the NAFLD score.
RESULTS: During a median follow-up of 78 months, median weight decreased from 119 to 78 kg (P < 0.0001), and median body mass index decreased from 45.2 to 29.0 kg/m2 (P < 0.0001). None of the patients developed clinical complications of liver disease, and none died due to liver-related causes. Median NAFLD score significantly decreased (P = 0.0005) during follow-up from - 0.929 (- 1.543 to - 0.561) to - 1.609 (- 2.056 to - 1.102). The NAFLD score category was unchanged in 32 patients (57%), improved in 18 (32%), and worsened in 6 (11%).
CONCLUSIONS: Patients with NAFLD and proven histological liver damage at surgery do not develop complications of liver disease in long term after bilio-pancreatic diversion. Moreover, noninvasive parameters of liver damage improve. Thus, preexisting liver damage does not seem to be a contraindication to bilio-pancreatic diversion.

Entities:  

Keywords:  Bariatric surgery; Cirrhosis; Liver fibrosis; Nonalcoholic fatty liver disease; Steatosis

Mesh:

Year:  2018        PMID: 29629490     DOI: 10.1007/s10620-018-5052-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

1.  Effect of Roux-en-Y gastric bypass on nonalcoholic fatty liver disease evaluated through NAFLD fibrosis score: a prospective study.

Authors:  Everton Cazzo; Laísa Simakawa Jimenez; José Carlos Pareja; Elinton Adami Chaim
Journal:  Obes Surg       Date:  2015-06       Impact factor: 4.129

2.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

3.  Long-term consequences after jejunoileal bypass for morbid obesity.

Authors:  M P Hocking; G L Davis; D A Franzini; E R Woodward
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

4.  Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease.

Authors:  Philippe Mathurin; Antoine Hollebecque; Laurent Arnalsteen; David Buob; Emmanuelle Leteurtre; Robert Caiazzo; Marie Pigeyre; Hélène Verkindt; Sébastien Dharancy; Alexandre Louvet; Monique Romon; François Pattou
Journal:  Gastroenterology       Date:  2009-05-04       Impact factor: 22.682

5.  The utility of the "NAFLD fibrosis score" in morbidly obese subjects with NAFLD.

Authors:  Kamran Qureshi; Ronald H Clements; Gary A Abrams
Journal:  Obes Surg       Date:  2008-01-24       Impact factor: 4.129

6.  The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.

Authors:  Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

7.  Does a calculated "NAFLD fibrosis score" reliably negate the need for liver biopsy in patients undergoing bariatric surgery?

Authors:  Kerri A Simo; Iain H McKillop; Matthew T McMillan; William A Ahrens; Amanda L Walters; Kyle J Thompson; Timothy S Kuwada; John B Martinie; David A Iannitti; Keith S Gersin; David Sindram
Journal:  Obes Surg       Date:  2014-01       Impact factor: 4.129

8.  Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis.

Authors:  John G Kral; Swan N Thung; Simon Biron; Frederic-Simon Hould; Stefane Lebel; Simon Marceau; Serge Simard; Picard Marceau
Journal:  Surgery       Date:  2004-01       Impact factor: 3.982

Review 9.  Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal.

Authors:  Mariana V Machado; Helena Cortez-Pinto
Journal:  J Hepatol       Date:  2012-11-23       Impact factor: 25.083

10.  Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

Authors:  Robert J Wong; Ramsey Cheung; Aijaz Ahmed
Journal:  Hepatology       Date:  2014-04-25       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.